Related Experiment Video
Updated: Mar 11, 2026
Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
[Chronic kidney disease and dyslipidaemia]
Vicente Pascual1, Adalberto Serrano2, Juan Pedro-Botet3
1Centro de Salud Palleter, Castellón, España.
Insights
Chronic kidney disease (CKD) is a high cardiovascular risk. Early intervention for dyslipidemia in CKD patients is crucial to reduce cardiovascular events and slow disease progression.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Chronic kidney disease (CKD) significantly elevates cardiovascular risk and mortality.
- Dyslipidemia accelerates CKD progression and atherosclerosis, increasing cardiovascular complications.
- Effective management of CKD and its comorbidities is essential for patient outcomes.
Purpose of the Study:
- To review lipid-lowering therapies for CKD patients.
- To emphasize early and intensive dyslipidemia management in CKD.
- To assess treatment adjustments based on disease progression and patient characteristics.
Main Methods:
- Literature review of therapeutic measures for dyslipidemia in CKD.
- Assessment of lipid-lowering strategies and their impact on cardiovascular events.
- Evaluation of treatment safety and efficacy, particularly statin therapy.
Main Results:
- Dyslipidemia control is vital for reducing cardiovascular morbidity and mortality in CKD.
- Early and intensive lipid management is a priority before significant kidney function decline.
- Statins are safe and effective for lowering LDL-Cholesterol and reducing cardiovascular events in CKD patients and post-transplant recipients, with less data for dialysis patients.
Conclusions:
- Optimizing lipid profiles in CKD patients is critical for cardiovascular risk reduction.
- Tailored lipid-lowering therapies, especially statins, should be implemented early in CKD management.
- Further research is needed on the efficacy of lipid-lowering treatments in dialysis patients.
Abstract:
Chronic kidney disease (CKD) has to be considered as a high, or even very high risk cardiovascular risk condition, since it leads to an increase in cardiovascular mortality that continues to increase as the disease progresses. An early diagnosis of CKD is required, together with an adequate identification of the risk factors, in order to slow down its progression to more severe states, prevent complications, and to delay, whenever possible, the need for renal replacement therapy. Dyslipidaemia is a factor of the progression of CKD that increases the risk in developing atherosclerosis and its complications. Its proper control contributes to reducing the elevated cardiovascular morbidity and mortality presented by these patients. In this review, an assessment is made of the lipid-lowering therapeutic measures required to achieve to recommended objectives, by adjusting the treatment to the progression of the disease and to the characteristics of the patient. In CKD, it seems that an early and intensive intervention of the dyslipidaemia is a priority before there is a significant decrease in kidney function. Treatment with statins has been shown to be safe and effective in decreasing LDL-Cholesterol, and in the reduction of cardiovascular events in individuals with CKD, or after renal transplant, although there is less evidence in the case of dialysed patients.
Related Concept Videos
01:24Chronic Kidney Disease II: Clinical Manifestations
01:25Chronic Kidney Disease I: Introduction
01:28Chronic Kidney Disease III: Interprofessional Care
01:18Chronic Kidney Disease IV: Nursing Management
01:24Nephrotic Syndrome I : Introduction
01:24Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...